Table 1.
Study cohort.
| Group | HC | pAPS | sAPS |
|---|---|---|---|
| n = 20 | n = 21 | n = 16 | |
|
age
(median [IQR]) |
42.50 [27.50, 63.75] |
49.00 [42.00, 60.00] |
50.50 [39.50, 58.75] |
| sex | |||
| w | 10 | 13 (62%) | 16 (100%) |
| m | 10 | 8 (38%) | 0 (0%) |
| underlying disease | |||
| SLE | – | – | 14 (88%) |
| SjD | – | – | 1 (6%) |
| UCTD | – | – | 1 (6%) |
| clinical manifestation | |||
| venous only | – | 4 (19%) | 5 (31%) |
| arterial only | – | 7 (33%) | 3 (19%) |
| arterial + venous | – | 9 (43%) | 5 (31%) |
| undefined phenotype | – | 1 (5%) | 3 (19%) |
| pregnancy complication | – | 4 (19%) | 1 (6%) |
| aPL antibodies | |||
| anti-β2GP1 | – | 18 (86%) | 7 (44%) |
| anti-cardiolipin | – | 19 (90%) | 7 (44%) |
| lupus anticoagulant | – | 16 (94%*) | 4 (100%*) |
| triple-positive | – | 14 (67%) | 3 (19%) |
| medication | |||
| low-dose acetylsalicylic acid | – | 6 (29%) | 2 (13%) |
| phenprocoumon | – | 17 (81%) | 7 (44%) |
| therapeutic heparin | – | 2 (10%) | 0 (0%) |
| antiplatelet agents/not ASS | – | 1 (5%) | 1 (6%) |
| glucocorticoids (1-20mg/d) | – | 4 (19%) | 12 (75%) |
| hydroxychloroquine | – | 6 (29%) | 9 (56%) |
| azathioprine | – | 0 (0%) | 5 (31%) |
| mycophenolate mofetil | – | 0 (0%) | 2 (13%) |
| methotrexate | – | 0 (0%) | 1 (6%) |
| tacrolimus | – | 0 (0%) | 1 (6%) |
| belimumab | – | 0 (0%) | 1 (6%) |
*of all patients tested.